# Pharmacogenetics of Response to GLP1R Agonists

> **NCT05071898** · PHASE1 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 600 (estimated)

## Conditions studied

- Obesity
- Diabetes Type 2

## Interventions

- **DRUG:** Semaglutide Pen Injector [Ozempic]

## Key facts

- **NCT ID:** NCT05071898
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-11
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05071898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05071898, "Pharmacogenetics of Response to GLP1R Agonists". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05071898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*